VBI VACCINES INC. (TSE:VBV) Files An 8-K Other EventsItem 8.01 Other Events.
On August 28, 2018, VBI Vaccines Inc. issued a press release announcing that Jeff Baxter, President and CEO, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release dated August 28, 2018 |
VBI Vaccines Inc/BC ExhibitEX-99.1 2 ex99-1.htm VBI Vaccines to Present at the 20th Annual Rodman & Renshaw Global Investment Conference CAMBRIDGE,…To view the full exhibit click here
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).
